Comparative Pharmacology
Head-to-head clinical analysis: NUROMAX versus SYNCURINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUROMAX versus SYNCURINE.
NUROMAX vs SYNCURINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neuromuscular blocking agent; competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing depolarization and muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and causing skeletal muscle paralysis.
0.1 mg/kg IV bolus, then 0.015 mg/kg IV as needed for neuromuscular blockade.
0.1-0.2 mg/kg IV bolus for paralysis, repeat 0.05-0.1 mg/kg as needed; maintenance infusion 0.5-1.5 mcg/kg/min IV.
None Documented
None Documented
Terminal half-life: 1.5-2.5 hours; prolonged in renal impairment (up to 5 hours) and hepatic disease
Terminal half-life: 2-5 hours (prolonged with renal impairment; up to 10 hours in severe impairment)
Renal: 80-90% unchanged; biliary: 10-20%
Primarily renal excretion (50-70% unchanged drug), with biliary/fecal elimination (10-20%)
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent